Literature DB >> 30393604

Immunotherapy efficacy and gender: discovery in precision medicine.

Bryan C Ulrich1, Nicolas Guibert2.   

Abstract

Year:  2018        PMID： 30393604      PMCID： PMC6193899          DOI： 10.21037/tlcr.2018.08.05

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


× No keyword cloud information.
  10 in total

1.  Tumor immunotherapy directed at PD-1.

Authors:  Antoni Ribas
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

Review 2.  Targeting the PD1/PD-L1 axis in melanoma: biological rationale, clinical challenges and opportunities.

Authors:  Barbara Merelli; Daniela Massi; Laura Cattaneo; Mario Mandalà
Journal:  Crit Rev Oncol Hematol       Date:  2013-08-28       Impact factor: 6.312

3.  Gender Disparity and Mutation Burden in Metastatic Melanoma.

Authors:  Sameer Gupta; Mykyta Artomov; William Goggins; Mark Daly; Hensin Tsao
Journal:  J Natl Cancer Inst       Date:  2015-08-20       Impact factor: 13.506

Review 4.  PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy.

Authors:  Sandip Pravin Patel; Razelle Kurzrock
Journal:  Mol Cancer Ther       Date:  2015-02-18       Impact factor: 6.261

5.  PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project.

Authors:  Fred R Hirsch; Abigail McElhinny; Dave Stanforth; James Ranger-Moore; Malinka Jansson; Karina Kulangara; William Richardson; Penny Towne; Debra Hanks; Bharathi Vennapusa; Amita Mistry; Rasika Kalamegham; Steve Averbuch; James Novotny; Eric Rubin; Kenneth Emancipator; Ian McCaffery; J Andrew Williams; Jill Walker; John Longshore; Ming Sound Tsao; Keith M Kerr
Journal:  J Thorac Oncol       Date:  2016-11-29       Impact factor: 15.609

6.  Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.

Authors:  Naiyer A Rizvi; Matthew D Hellmann; Alexandra Snyder; Pia Kvistborg; Vladimir Makarov; Jonathan J Havel; William Lee; Jianda Yuan; Phillip Wong; Teresa S Ho; Martin L Miller; Natasha Rekhtman; Andre L Moreira; Fawzia Ibrahim; Cameron Bruggeman; Billel Gasmi; Roberta Zappasodi; Yuka Maeda; Chris Sander; Edward B Garon; Taha Merghoub; Jedd D Wolchok; Ton N Schumacher; Timothy A Chan
Journal:  Science       Date:  2015-03-12       Impact factor: 47.728

7.  Clinical Significance of PD-L1 Protein Expression in Surgically Resected Primary Lung Adenocarcinoma.

Authors:  Kazuki Takada; Tatsuro Okamoto; Fumihiro Shoji; Mototsugu Shimokawa; Takaki Akamine; Shinkichi Takamori; Masakazu Katsura; Yuzo Suzuki; Takatoshi Fujishita; Gouji Toyokawa; Yosuke Morodomi; Shinji Okano; Yoshinao Oda; Yoshihiko Maehara
Journal:  J Thorac Oncol       Date:  2016-06-23       Impact factor: 15.609

8.  Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis.

Authors:  Fabio Conforti; Laura Pala; Vincenzo Bagnardi; Tommaso De Pas; Marco Martinetti; Giuseppe Viale; Richard D Gelber; Aron Goldhirsch
Journal:  Lancet Oncol       Date:  2018-05-16       Impact factor: 41.316

9.  Tumor Mutational Burden and Response Rate to PD-1 Inhibition.

Authors:  Mark Yarchoan; Alexander Hopkins; Elizabeth M Jaffee
Journal:  N Engl J Med       Date:  2017-12-21       Impact factor: 91.245

10.  Analysis of ultra-deep targeted sequencing reveals mutation burden is associated with gender and clinical outcome in lung adenocarcinoma.

Authors:  Dakai Xiao; Hui Pan; Fuqiang Li; Kui Wu; Xin Zhang; Jianxing He
Journal:  Oncotarget       Date:  2016-04-19
  10 in total
  3 in total

1.  Treatment patterns, clinical outcomes, and healthcare resource use associated with advanced/metastatic lung cancer in China: protocol for a retrospective observational study.

Authors:  Bin Qiu; Gaofeng Li; Feng Luo; Xiaohong Cai; Lin Wu; Jianhua Chen; Yanping Hu; Zhiliu Tang; Shuo Yang; Jie He
Journal:  Transl Lung Cancer Res       Date:  2020-12

2.  Differences in men and women suffering from CRSwNP and AERD in quality of life.

Authors:  Tina J Bartosik; David T Liu; Nicholas J Campion; Sergio Villazala-Merino; Stefan Janik; Valerie Dahm; Christian A Mueller; Erich Vyskocil; Victoria Stanek; Tamara Quint; Christine Bangert; Julia Eckl-Dorna; Sven Schneider
Journal:  Eur Arch Otorhinolaryngol       Date:  2020-10-15       Impact factor: 2.503

3.  Impact of clinicopathological features on the efficacy of immune checkpoint inhibitors plus conventional treatment in patients with advanced lung cancer.

Authors:  Guanghui Gao; Meng Qiao; Hongcheng Liu; Tao Jiang; Fei Zhou; Xuefei Li; Chao Zhao; Xiaoxia Chen; Chunxia Su; Shengxiang Ren; Caicun Zhou
Journal:  J Thorac Dis       Date:  2019-09       Impact factor: 2.895
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.